Scpharmaceuticals INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
scPharmaceuticals Director Frederick M. Hudson's stock options were converted to cash and CVRs following the company's merger with MannKind Corporation.
scPharmaceuticals CFO Rachael Nokes reported the disposition of common stock and stock options following the company's acquisition by MannKind Corporation.
scPharmaceuticals Inc. President and CEO John H. Tucker's equity holdings were converted into cash and contingent value rights following the merger with MannKind Corporation.
scPharmaceuticals Director Sara Bonstein's stock options were cancelled and converted into cash and Contingent Value Rights following the completion of a tender offer by MannKind Corporation.
Leonard D. Schaeffer, a director of scPharmaceuticals Inc., reported the disposition of all his common stock and stock options following the company's acquisition by MannKind Corporation.
scPharmaceuticals Director Klaus Veitinger's stock options were cancelled and converted to cash and CVRs following the completion of a tender offer by MannKind Corporation.
scPharmaceuticals Director William Tober converted all his stock options into cash and Contingent Value Rights following the completion of a tender offer by MannKind Corporation.
A director of scPharmaceuticals Inc. converted all outstanding stock options into cash and Contingent Value Rights following the completion of a tender offer by MannKind Corporation.
scPharmaceuticals Director Mette Kirstine Agger's stock options were cancelled and converted into cash and Contingent Value Rights following the completion of a tender offer by MannKind Corporation.
Director Jack A. Khattar disposed of all scPharmaceuticals Inc. common stock and stock options following the company's merger with MannKind Corporation.
Mette Kirstine Agger, a Director at scPharmaceuticals Inc., was granted 30,000 stock options with an exercise price of $3.85, vesting by June 2026 or the next annual meeting.
Minnie Baylor-Henry, a Director at scPharmaceuticals Inc., was granted 30,000 stock options with an exercise price of $3.85, vesting by June 2026 or the next annual meeting.
scPharmaceuticals Inc. Director Sara Bonstein was granted 30,000 stock options with an exercise price of $3.85, vesting fully by June 2026 or the next annual meeting.
scPharmaceuticals Inc. Director Frederick M. Hudson was granted 30,000 stock options with an exercise price of $3.85, aligning his interests with shareholder value.
Jack A. Khattar, a Director of scPharmaceuticals Inc., was granted 30,000 stock options with an exercise price of $3.85, vesting by June 2026 or the next annual meeting.
Dr. Klaus R. Veitinger, a Director at scPharmaceuticals Inc., was granted 30,000 stock options with an exercise price of $3.85, vesting by June 2026 or the next annual meeting.
William Tober Abraham, a Director at scPharmaceuticals Inc., has acquired 30,000 stock options with an exercise price of $3.85, vesting by June 2026 or the next annual meeting.
scPharmaceuticals Inc. Director Leonard D. Schaeffer has acquired 30,000 stock options with an exercise price of $3.85, vesting by June 2026 or the next annual meeting.
scPharmaceuticals' CEO, John H. Tucker, reports the acquisition of 200,000 shares of common stock and 300,000 stock options.
Rachael Nokes, CFO and Treasurer of scPharmaceuticals Inc., reports the acquisition of restricted stock units and stock options.
Rachael Nokes, CFO and Treasurer of scPharmaceuticals Inc., sold 5,235 shares of common stock on January 3, 2025, to cover tax obligations related to vesting restricted stock units.
John H. Tucker, CEO of scPharmaceuticals Inc., sold 13,360 shares of common stock on January 3, 2025, to satisfy tax withholding obligations related to vesting restricted stock units.
Director Leonard D. Schaeffer exercised stock options in scPharmaceuticals Inc. on August 26, 2024, resulting in the acquisition of common stock.
Rachael Nokes, CFO and Treasurer of scPharmaceuticals Inc., amended a Form 4 filing to correct the price of securities acquired on August 6, 2024.
OrbiMed Advisors and related entities increase their holdings in scPharmaceuticals through purchases in an underwritten public offering.
Rachael Nokes, CFO and Treasurer of scPharmaceuticals Inc., reports exercising stock options and adjusting previously reported option numbers.
Leonard D. Schaeffer, a director of scPharmaceuticals Inc., acquired stock options for 19,750 shares on June 11, 2024.
Mette Kirstine Agger, a director at scPharmaceuticals Inc., acquired stock options for 19,750 shares on June 11, 2024.
Director Frederick M. Hudson of scPharmaceuticals Inc. reports acquisition of stock options.
Director Jack A. Khattar acquired 19,750 stock options in scPharmaceuticals Inc. on June 11, 2024.